These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21441227)

  • 21. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
    Herrmann E; Zeuzem S; Sarrazin C; Hinrichsen H; Benhamou Y; Manns MP; Reiser M; Reesink H; Calleja JL; Forns X; Steinmann GG; Nehmiz G
    Antivir Ther; 2006; 11(3):371-6. PubMed ID: 16759054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.
    Flores MV; Strawbridge J; Ciaramella G; Corbau R
    Biochim Biophys Acta; 2009 Oct; 1794(10):1441-8. PubMed ID: 19505593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 24. "Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors.
    Lemon SM; Yi M; Li K
    Hepatology; 2005 Mar; 41(3):671-4. PubMed ID: 15723328
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
    Lin C; Lin K; Luong YP; Rao BG; Wei YY; Brennan DL; Fulghum JR; Hsiao HM; Ma S; Maxwell JP; Cottrell KM; Perni RB; Gates CA; Kwong AD
    J Biol Chem; 2004 Apr; 279(17):17508-14. PubMed ID: 14766754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
    Cubero M; Esteban JI; Otero T; Sauleda S; Bes M; Esteban R; Guardia J; Quer J
    Virology; 2008 Jan; 370(2):237-45. PubMed ID: 18006035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells.
    Salloum S; Kluge SF; Kim AY; Roggendorf M; Timm J
    Antiviral Res; 2010 Aug; 87(2):272-5. PubMed ID: 20488208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
    Hinrichsen H; Benhamou Y; Wedemeyer H; Reiser M; Sentjens RE; Calleja JL; Forns X; Erhardt A; Crönlein J; Chaves RL; Yong CL; Nehmiz G; Steinmann GG
    Gastroenterology; 2004 Nov; 127(5):1347-55. PubMed ID: 15521004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.
    Kneteman NM; Weiner AJ; O'Connell J; Collett M; Gao T; Aukerman L; Kovelsky R; Ni ZJ; Zhu Q; Hashash A; Kline J; Hsi B; Schiller D; Douglas D; Tyrrell DL; Mercer DF
    Hepatology; 2006 Jun; 43(6):1346-53. PubMed ID: 16729319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
    Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061.
    Shu C; Zeng X; Hao MH; Wei X; Yee NK; Busacca CA; Han Z; Farina V; Senanayake CH
    Org Lett; 2008 Mar; 10(6):1303-6. PubMed ID: 18293994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
    J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural characterization of the Hepatitis C Virus NS3 protease from genotype 3a: the basis of the genotype 1b vs. 3a inhibitor potency shift.
    Gallo M; Bottomley MJ; Pennestri M; Eliseo T; Paci M; Koch U; Bazzo R; Summa V; Carfì A; Cicero DO
    Virology; 2010 Sep; 405(2):424-38. PubMed ID: 20630554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.